沈骏;冉志华;

• 1:上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所上海市炎症性肠病研究中心

摘要(Abstract)：

炎症性肠病(inflammatory bowel disease,IBD)是一种慢性、复发性疾病,严重影响患者的生活质量。IBD的确切发病原因尚不清楚。目前研究显示,免疫系统异常激活、遗传易感性和黏膜屏障缺陷引起的肠道菌群改变,可能在IBD的致病机制中发挥综合作用。现有的IBD治疗方案包括常规药物治疗、内镜治疗和手术治疗。遗憾的是,IBD目前很难被完全治愈,因此需要更多治疗方案应对不同患者。随着IBD的治疗进入再生医学时代,干细胞治疗显示出治疗前景。干细胞治疗包括造血干细胞治疗和间充质干细胞治疗,传统治疗无效时显示出改善患者临床疾病活动性潜能。造血干细胞移植治疗的目的是破坏导致疾病的慢性"自身反应性"免疫细胞,并重新建立肠道对微生物的耐受性。在肛周瘘管型克罗恩病中,间充质干细胞移植的目的是将间充质干细胞局部沉积在瘘管中,以减轻局部免疫反应并诱导伤口愈合。本文对即将应用于临床的干细胞移植方法和正在进行的临床试验结果进行综述,以期为临床使用干细胞移植作为IBD潜在治疗方法提供思路。

关键词(KeyWords)： 炎症性肠病;造血干细胞治疗;间充质干细胞治疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(81770545)

作者(Authors): 沈骏;冉志华;

参考文献(References)：

• [1]MISSELWITZ B,JUILLERAT P,SULZ M C,et al.Emerging Treatment Options in Inflammatory Bowel Disease:Janus Kinases,Stem Cells,and More[J].Digestion,2020,101 Suppl 1:69-82.
• [2]GAZOULI M,ROUBELAKIS M G,THEODOROPOULOS G E.Stem cells as potential targeted therapy for inflammatory bowel disease[J].Inflamm Bowel Dis,2014,20(5):952-955.
• [3]KAPLAN G G,WINDSOR J W.The four epidemiological stages in the global evolution of inflammatory bowel disease[J].Nat Rev Gastroenterol Hepatol,2021,18(1):56-66.
• [4]NG S C,SHI H Y,HAMIDI N,et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:a systematic review of population-based studies[J].Lancet,2017,390(10114):2769-2778.
• [5]KAPLAN G G,NG S C.Globalisation of inflammatory bowel disease:perspectives from the evolution of inflammatory bowel disease in the UK and China[J].Lancet Gastroenterol Hepatol 2016,1(4):307-316.
• [6]MOLODECKY N A,SOON I S,RABI D M,et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review[J].Gastroenterology 2012,142(1):46-54 e42;quiz e30.
• [7]COWARD S,CLEMENT F,BENCHIMOL E I,et al.Past and Future Burden of Inflammatory Bowel Diseases Based on Mode-ling of Population-Based Data[J].Gastroenterology,2019,156(5):1345-1353.e4.
• [8]KAPLAN G G,NG S C.Understanding and Preventing the Global Increase of Inflammatory Bowel Disease[J].Gastro-enterology,2017,152(2):313-321.e2.
• [9]ROGLER G,VAVRICKA S,SCHOEPFER A,et al.Mucosal healing and deep remission:what does it mean?[J].World J Gastroenterol,2013,19(43):7552-7560.
• [10]HOMMES D,COLOMBEL J F,EMERY P,et al.Changing Crohn's disease management:need for new goals and indices to prevent disability and improve quality of life[J].J Crohns Colitis,2012,6 Suppl 2:S224-S234.
• [11]ABRAHAM B P,AHMED T,ALI T.Inflammatory Bowel Disease:Pathophysiology and Current Therapeutic Approaches[J].Handb Exp Pharmacol,2017,239:115-146.
• [12]WRIGHT E K,DING N S,NIEWIADOMSKI O.Management of inflammatory bowel disease[J].Med J Aust,2018,209(7):318-323.
• [13]THOMAS A,LODHIA N.Advanced therapy for inflammatory bowel disease:a guide for the primary care physician[J].J Am Board Fam Med,2014,27(3):411-420.
• [14]HESLOP J A,HAMMOND T G,SANTERAMO I,et al.Concise review:workshop review:understanding and assessing the risks of stem cell-based therapies[J].Stem Cells Transl Med,2015,4(4):389-400.
• [15]DA SILVA MEIRELLES L,CHAGASTELLES P C,NARDI N B.Mesenchymal stem cells reside in virtually all post-natal organs and tissues[J].J Cell Sci,2006,119(Pt 11):2204-2213.
• [16]KAVANAGH D P,KALIA N.Hematopoietic stem cell homing to injured tissues[J].Stem Cell Rev Rep,2011,7(3):672-682.
• [17]MARTíNEZ-MONTIEL MDEL P,GóMEZ-GóMEZ G J,FLORES A I.Therapy with stem cells in inflammatory bowel disease[J].World J Gastroenterol,2014,20(5):1211-1227.
• [18]BURT R K,CRAIG R M,MILANETTI F,et al.Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease:long-term follow-up[J].Blood,2010,116(26):6123-6132.
• [19]CLERICI M,CASSINOTTI A,ONIDA F,et al.Immunom-odulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease[J].Dig Liver Dis,2011,43(12):946-952.
• [20]OYAMA Y,CRAIG R M,TRAYNOR A E,et al.Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease[J].Gastroenterology,2005,128(3):552-563.
• [21]HASSELBLATT P,DROGNITZ K,POTTHOFF K,et al.Remission of refractory Crohn's disease by high-dose cycloph-osphamide and autologous peripheral blood stem cell transp-lantation[J].Aliment Pharmacol Ther,2012,36(8):725-735.
• [22]HAWKEY C J,ALLEZ M,CLARK M M,et al.Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease:A Randomized Clinical Trial[J].JAMA,2015,314(23):2524-2534.
• [23]RUIZ M A,JUNIOR R L K,PIRON-RUIZ L,et al.Medical,ethical,and legal aspects of hematopoietic stem cell transplantation for Crohn's disease in Brazil[J].World J Stem Cells,2020,12(10):1113-1123.
• [24]ELJARRAH A,GERGUES M,POBIARZYN P W,et al.Therapeutic Potential of Mesenchymal Stem Cells in Immune-Mediated Diseases[J].Adv Exp Med Biol,2019,1201:93-108.
• [25]KIMBREL E A,KOURIS N A,YAVANIAN G J,et al.Mesenc-hymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties[J].Stem Cells Dev,2014,23(14):1611-1624.
• [26]MAYNE C G,WILLIAMS C B.Induced and natural regulatory T cells in the development of inflammatory bowel disease[J].Inflamm Bowel Dis,2013,19(8):1772-1788.
• [27]LAZEBNIK L B,KNYAZEV O V,PARFENOV A I,et al.Optimization of cell therapy in patients with inflammatory bowel diseases[J].Ter Arkh,2012,84(8):10-17.
• [28]LIANG J,ZHANG H,WANG D,et al.Allogeneic mesenc-hymal stem cell transplantation in seven patients with refractory inflammatory bowel disease[J].Gut,2012,61(3):468-469.
• [29]SHI X,CHEN Q,WANG F.Mesenchymal stem cells for the treatment of ulcerative colitis:a systematic review and meta-analysis of experimental and clinical studies[J].Stem Cell Res Ther,2019,10(1):266.
• [30]ZHANG J,LV S,LIU X,et al.Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease:A Randomized Controlled Clinical Trial[J].Gut Liver,2018,12(1):73-78.
• [31]FORBES G M,STURM M J,LEONG R W,et al.A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy[J].Clin Gastroe-nterol Hepatol,2014,12(1):64-71.
• [32]GARCíA-OLMO D,GARCíA-ARRANZ M,GARCíA L G,et al.Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease:a new cell-based therapy[J].Int J Colorectal Dis,2003,18(5):451-454.
• [33]GARCíA-OLMO D,GARCíA-ARRANZ M,HERREROS D,et al.A phase Ⅰ clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation[J].Dis Colon Rectum,2005,48(7):1416-1423.
• [34]GARCIA-OLMO D,HERREROS D,PASCUAL I,et al.Expa-nded adipose-derived stem cells for the treatment of complex perianal fistula:a phase Ⅱ clinical trial[J].Dis Colon Rectum,2009,52(1):79-86.
• [35]CHO Y B,LEE W Y,PARK K J,et al.Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula:a phase Ⅰ clinical study[J].Cell Transplant,2013,22(2):279-285.
• [36]LEE W Y,PARK K J,CHO Y B,et al.Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula[J].Stem Cells,2013,31:2575-2581.
• [37]CHO Y B,PARK K J,YOON S N,et al.Long-term results of adipose-derived stem cell therapy for the treatment of Crohn's fistula[J].Stem Cells Transl Med,2015,4(5):532-537.
• [38]CICCOCIOPPO R,BERNARDO M E,SGARELLA A,et al.Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease[J].Gut,2011,60(6):788-798.
• [39]DE LA PORTILLA F,ALBA F,GARCíA-OLMO D,et al.Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease:results from a multicenter phase Ⅰ/Ⅱa clinical trial[J].Int J Color-ectal Dis,2013,28(3):313-323.
• [40]PANéS J,GARCíA-OLMO D,VAN ASSCHE G,et al.Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease:a phase 3 randomised,double-blind controlled trial[J].Lancet,2016,388(10051):1281-1290.
• [41]MOLENDIJK I,BONSING B A,ROELOFS H,et al.Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease[J].Gastroenterology,2015,149(4):918-927.e6.
• [42]DIETZ A B,DOZOIS E J,FLETCHER J G,et al.Autologous Mesenchymal Stem Cells,Applied in a Bioabsorbable Matrix,for Treatment of Perianal Fistulas in Patients With Crohn's Disease[J].Gastroenterology,2017,153(1):59-62.e2.
• [43]SCOTT L J.Darvadstrocel:A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn's Disease[J].BioDrugs,2018,32(6):627-634.
• [44]PANéS J,GARCíA-OLMO D,VAN ASSCHE G,et al.Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease[J].Gastroenterology,2018,154(5):1334-1342.e4.
• [45]WAINSTEIN C,QUERA R,FLUXá D,et al.Stem Cell Therapy in Refractory Perineal Crohn's Disease:Long-term Follow-up[J].Colorectal Dis,2018,20(3):O68-O75.
• [46]AVIVAR-VALDERAS A,MARTíN-MARTíN C,RAMíREZ C,et al.Dissecting Allo-Sensitization After Local Administration of Human Allogeneic Adipose Mesenchymal Stem Cells in Perianal Fistulas of Crohn's Disease Patients[J].Front Immunol,2019,10:1244.
• [47]DIGE A,HOUGAARD H T,AGNHOLT J,et al.Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohn's Disease[J].Gastroenterology,2019,156:2208-2216.e1.
• [48]ZHOU C,LI M,ZHANG Y,et al.Autologous adipose-derived stem cells for the treatment of Crohn's fistula-in-ano:an open-label,controlled trial[J].Stem Cell Res Ther,2020,11(1):124.
• [49]BARNHOORN M C,WASSER M,ROELOFS H,et al.Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas[J].J Crohns Colitis,2020,14(1):64-70.
• [50]LIGHTNER A L,DOZOIS E J,DIETZ A B,et al.Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohn's Fistulas[J].Inflamm Bowel Dis,2020,26(5):670-677.